NASDAQ:RGLS Regulus Therapeutics (RGLS) Stock Forecast, Price & News $1.28 +0.00 (+0.27%) (As of 03:28 PM ET) Add Compare Share Share Today's Range$1.27▼$1.3150-Day Range$1.27▼$1.7652-Week Range$0.76▼$2.14Volume23,825 shsAverage Volume46,652 shsMarket Capitalization$25.00 millionP/E RatioN/ADividend YieldN/APrice Target$10.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Regulus Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside708.9% Upside$10.50 Price TargetShort InterestHealthy1.12% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.44Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.52) to ($1.19) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.35 out of 5 starsMedical Sector299th out of 961 stocksPharmaceutical Preparations Industry124th out of 456 stocks 3.5 Analyst's Opinion Consensus RatingRegulus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.50, Regulus Therapeutics has a forecasted upside of 708.9% from its current price of $1.30.Amount of Analyst CoverageRegulus Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.12% of the float of Regulus Therapeutics has been sold short.Short Interest Ratio / Days to CoverRegulus Therapeutics has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Regulus Therapeutics has recently decreased by 10.23%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldRegulus Therapeutics does not currently pay a dividend.Dividend GrowthRegulus Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RGLS. Previous Next 2.5 News and Social Media Coverage News SentimentRegulus Therapeutics has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Regulus Therapeutics this week, compared to 1 article on an average week.Search Interest2 people have searched for RGLS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Regulus Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.41% of the stock of Regulus Therapeutics is held by insiders.Percentage Held by Institutions62.22% of the stock of Regulus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Regulus Therapeutics are expected to grow in the coming year, from ($1.52) to ($1.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Regulus Therapeutics is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Regulus Therapeutics is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRegulus Therapeutics has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Regulus Therapeutics (NASDAQ:RGLS) StockRegulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.Read More RGLS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RGLS Stock News HeadlinesSeptember 23, 2023 | americanbankingnews.comRegulus Therapeutics (NASDAQ:RGLS) Price Target Increased to $12.00 by Analysts at Canaccord Genuity GroupSeptember 22, 2023 | msn.comCanaccord Genuity Maintains Regulus Therapeutics (RGLS) Buy RecommendationSeptember 25, 2023 | UNKNOWN (Ad)Space CEO Featured on Good Morning AmericaA $25 Billion Earth Observation Market by 2040. Learn moreSeptember 21, 2023 | markets.businessinsider.comAnalyst Expectations for Regulus Therapeutics's FutureSeptember 21, 2023 | americanbankingnews.comRegulus Therapeutics (NASDAQ:RGLS) Research Coverage Started at StockNews.comSeptember 20, 2023 | msn.comRegulus Therapeutics Releases Early Data From Of Investigational For Rare Type Of Kidney DiseaseSeptember 20, 2023 | markets.businessinsider.comRegulus Reports Positive Topline Data From First Cohort Of Patients In Phase 1b Study Of RGLS8429September 20, 2023 | finance.yahoo.comRegulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)September 25, 2023 | UNKNOWN (Ad)Space CEO Featured on Good Morning AmericaA $25 Billion Earth Observation Market by 2040. Learn moreSeptember 20, 2023 | americanbankingnews.comRegulus Therapeutics (NASDAQ:RGLS) Given Buy Rating at HC WainwrightSeptember 15, 2023 | americanbankingnews.comRegulus Therapeutics (NASDAQ:RGLS) Now Covered by Analysts at StockNews.comSeptember 13, 2023 | finance.yahoo.comRegulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)September 5, 2023 | finance.yahoo.comRegulus Therapeutics Announces Participation at Two Healthcare Investment ConferencesAugust 24, 2023 | gurufocus.comRegulus Therapeutics (RGLS): An Attractive Valuation or a Potential Value Trap?August 23, 2023 | finance.yahoo.comRegulus Therapeutics Inc's Uncertain Future: Understanding the Barriers to OutperformanceAugust 23, 2023 | finance.yahoo.comRegulus Therapeutics to Host Virtual Investor Event on September 6, 2023August 9, 2023 | markets.businessinsider.comRegulus (RGLS) Gets a Buy from H.C. WainwrightAugust 8, 2023 | finance.yahoo.comRegulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent UpdatesAugust 2, 2023 | finance.yahoo.comRegulus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth ConferenceJuly 18, 2023 | finance.yahoo.comRegulus Therapeutics to Present at the H.C. Wainwright 2nd Annual Kidney ConferenceJune 28, 2023 | markets.businessinsider.comExpert Ratings for Regulus TherapeuticsJune 28, 2023 | markets.businessinsider.comH.C. Wainwright Remains a Buy on Regulus (RGLS)June 27, 2023 | finance.yahoo.comRegulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)June 23, 2023 | finance.yahoo.comRegulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of DirectorsJune 20, 2023 | finance.yahoo.comRegulus Therapeutics Announces Update on Preclinical Studies in Amyotrophic Lateral Sclerosis in Collaboration with Researchers from Harvard's Brigham and Women's HospitalJune 16, 2023 | fool.comRegulus Therapeutics (NASDAQ: RGLS)June 12, 2023 | finance.yahoo.comRegulus Therapeutics Strengthens Research & Development LeadershipSee More Headlines Receive RGLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regulus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address RGLS Company Calendar Last Earnings8/08/2023Today9/25/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:RGLS CUSIP75915K10 CIK1505512 Webwww.regulusrx.com Phone(858) 202-6300FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Forecast$10.50 High Stock Price Forecast$12.00 Low Stock Price Forecast$9.00 Forecasted Upside/Downside+720.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,320,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-85.37% Return on Assets-63.50% Debt Debt-to-Equity RatioN/A Current Ratio5.03 Quick Ratio5.03 Sales & Book Value Annual Sales$10.01 million Price / Sales2.49 Cash FlowN/A Price / Cash FlowN/A Book Value$2.27 per share Price / Book0.56Miscellaneous Outstanding Shares19,480,000Free Float17,845,000Market Cap$24.93 million OptionableOptionable Beta1.65 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Joseph P. Hagan M.B.A. (Age 54)CEO & Director Comp: $920.73kMs. Crispina Calsada CPA (Age 53)Chief Financial Officer Comp: $500.87kMr. Christopher Ray Aker J.D. (Age 62)Sr. VP, Gen. Counsel & Corp. Sec. Comp: $524.79kDr. Preston S. Klassen M.D. (Age 54)M.H.S., Pres and Head of R&D Mr. Daniel J. Penksa (Age 37)Exec. Director of Fin. & Controller Dr. Claire Susan Padgett M.S.M.T., Ph.D., Sr. VP of Clinical OperationsDr. Rekha Garg M.D.M.S., Sr. VP of Clinical Devel. & RegulatoryMore ExecutivesKey CompetitorsMolecular TemplatesNASDAQ:MTEMBolt BiotherapeuticsNASDAQ:BOLTCatalyst BiosciencesNASDAQ:CBIOFortress BiotechNASDAQ:FBIOASLAN PharmaceuticalsNASDAQ:ASLNView All CompetitorsInstitutional OwnershipCitadel Advisors LLCBought 100 shares on 8/15/2023Ownership: 0.000%Prelude Capital Management LLCBought 40,660 shares on 8/14/2023Ownership: 0.209%Geode Capital Management LLCBought 38,049 shares on 8/11/2023Ownership: 0.578%Renaissance Technologies LLCBought 7,300 shares on 8/11/2023Ownership: 0.237%View All Institutional Transactions RGLS Stock - Frequently Asked Questions Should I buy or sell Regulus Therapeutics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Regulus Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RGLS shares. View RGLS analyst ratings or view top-rated stocks. What is Regulus Therapeutics' stock price forecast for 2023? 2 brokerages have issued twelve-month price targets for Regulus Therapeutics' stock. Their RGLS share price forecasts range from $9.00 to $12.00. On average, they predict the company's share price to reach $10.50 in the next year. This suggests a possible upside of 720.3% from the stock's current price. View analysts price targets for RGLS or view top-rated stocks among Wall Street analysts. How have RGLS shares performed in 2023? Regulus Therapeutics' stock was trading at $1.37 at the start of the year. Since then, RGLS stock has decreased by 6.6% and is now trading at $1.28. View the best growth stocks for 2023 here. When is Regulus Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our RGLS earnings forecast. How were Regulus Therapeutics' earnings last quarter? Regulus Therapeutics Inc. (NASDAQ:RGLS) posted its quarterly earnings data on Tuesday, August, 8th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.39) by $0.02. When did Regulus Therapeutics' stock split? Regulus Therapeutics shares reverse split on the morning of Wednesday, June 29th 2022. The 1-10 reverse split was announced on Wednesday, June 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What is Joseph Hagan's approval rating as Regulus Therapeutics' CEO? 2 employees have rated Regulus Therapeutics Chief Executive Officer Joseph Hagan on Glassdoor.com. Joseph Hagan has an approval rating of 49% among the company's employees. This puts Joseph Hagan in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Regulus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Regulus Therapeutics investors own include Aduro Biotech (ADRO), Flexion Therapeutics (FLXN), Cytori Therapeutics (CYTX), PTC Therapeutics (PTCT), Novavax (NVAX), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Gilead Sciences (GILD), Synergy Pharmaceuticals (SGYP) and Trevena (TRVN). What is Regulus Therapeutics' stock symbol? Regulus Therapeutics trades on the NASDAQ under the ticker symbol "RGLS." Who are Regulus Therapeutics' major shareholders? Regulus Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (0.58%), Renaissance Technologies LLC (0.24%), Prelude Capital Management LLC (0.21%) and Citadel Advisors LLC (0.00%). Insiders that own company stock include Christopher Ray Aker, Denis Drygin, Joseph P Hagan and Paul Edward Walker. View institutional ownership trends. How do I buy shares of Regulus Therapeutics? Shares of RGLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Regulus Therapeutics' stock price today? One share of RGLS stock can currently be purchased for approximately $1.28. How much money does Regulus Therapeutics make? Regulus Therapeutics (NASDAQ:RGLS) has a market capitalization of $24.93 million and generates $10.01 million in revenue each year. The biopharmaceutical company earns $-28,320,000.00 in net income (profit) each year or ($1.69) on an earnings per share basis. How can I contact Regulus Therapeutics? Regulus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. The official website for the company is www.regulusrx.com. The biopharmaceutical company can be reached via phone at (858) 202-6300 or via email at ccalsada@regulusrx.com. This page (NASDAQ:RGLS) was last updated on 9/25/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regulus Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.